Seattle Genetics, Inc. (NASDAQ:SGEN) Files An 8-K Other EventsItem 8.01Other Events.
Seattle Genetics, Inc. (the “Company”) is filing this Current Report on Form 8-K to provide a copy of the legal opinion of Cooley LLP relating to the legality of the Company’s common stock, par value $0.001 per share, to be offered and sold the Company’s Registration Statement on Form S-3 (File No.333-222793) and the related prospectus supplement, dated July26, 2018, and filed with the U.S. Securities and Exchange Commission to Rule 424 under the Securities Act.
Item 8.01Financial Statements and Exhibits.
(d)Exhibits.
SEATTLE GENETICS INC /WA ExhibitEX-5.1 2 d533119dex51.htm EX-5.1 EX-5.1 Exhibit 5.1 July 26,…To view the full exhibit click here
About Seattle Genetics, Inc. (NASDAQ:SGEN)
Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company’s product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). The Company’s pipeline includes other clinical-stage ADC programs, which are SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. SGN-CD33A is an ADC composed of an anti-CD33 monoclonal antibody indicated for the treatment of acute myeloid leukemia (AML). SGN-CD19A is an ADC composed of an anti-CD19 monoclonal antibody indicated for the treatment of hematologic malignancies. SGN-LIV1A is an ADC composed of an anti-LIV-1 monoclonal antibody indicated for the treatment of LIV-1-positive metastatic breast cancer.